All Posts: aging
-
Steroid Originally Discovered in the Dogfish Shark Attacks Parkinson’s-Related Toxin in Animal Model
A naturally occurring steroid made by the dogfish shark prevents the buildup of a lethal protein in animal studies, reports an international team of researchers. The clustering of this protein, alpha-synuclein (α-synuclein), is the hallmark of Parkinson’s disease and dementia with Lewy bodies, suggesting a new potential compound for therapeutic research.
Category: News Release
-
Nobel Prize-winning Science is Key to Georgetown Neurotherapeutic Research
Today, the 2016 Nobel Prize in the category of medicine or physiology was awarded to Yoshinori Ohsumi “for his discoveries of mechanisms for autophagy,” a fundamental process for degrading and recycling cellular components.
Category: GUMC Stories
-
Georgetown Receives FDA Clearance to Conduct Clinical Trial with Nilotinib in Alzheimer’s Disease
Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer’s disease.
Category: News Release
-
Resveratrol Appears to Restore Blood-Brain Barrier Integrity in Alzheimer’s Disease
TORONTO (July 27, 2016) — Resveratrol, given to Alzheimer’s patients, appears to restore the integrity of the blood-brain barrier, reducing the ability of harmful immune molecules secreted by immune cells to infiltrate from the body into brain tissues, say researchers at Georgetown University Medical Center. The reduction in neuronal inflammation slowed the cognitive decline of patients, […]
Category: News Release
-
More Evidence in Quest to Repurpose Cancer Drugs for Alzheimer’s Disease
TORONTO – An FDA approved drug to treat renal cell carcinoma appears to reduce levels of a toxic brain protein linked to dementia in Alzheimer’s and Parkinson’s diseases when given to animals. This finding is the latest from Georgetown University Medical Center’s Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases.
Category: News Release
-
Study: Cancer Drug Restores Brain Dopamine, Reduces Toxic Proteins in Parkinson, Dementia
MEDIA CONTACT:Karen Teberkm463@georgetown.edu WASHINGTON (July 11, 2016) — A small proof of concept study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson’s disease or dementia with Lewy bodies. Dopamine is the brain chemical (neurotransmitter) lost as a result […]
Category: News Release
-
Georgetown Alzheimer’s Researcher Has “BrightFocus”
(June 12, 2016) — Xiong Jiang, PhD, believes there is a way to identify patients at an early enough stage in Alzheimer’s disease — well before clinical symptoms crop up — that they could be effectively treated with novel agents. His ideas have earned him a 3-year $300,000 grant from the BrightFocus Foundation, and on […]
Category: GUMC Stories
-
Georgetown University and The Michael J. Fox Foundation for Parkinson’s Research Offer Fellowship in Regulatory Science
WASHINGTON and NEW YORK — Georgetown University Medical Center and The Michael J. Fox Foundation for Parkinson’s Research announce a fellowship in regulatory science that will promote postgraduate training in the Parkinson’s research field to optimize clinical trial design and support approval of novel therapies.
Category: News Release
-
“SNIFF,” a Nasal Insulin Study for Alzheimer’s, Now Underway at Georgetown
WASHINGTON – Georgetown University’s Memory Disorders Program is looking for volunteers to participate in a study to see if insulin, the hormone used to treat diabetes, can improve cognition, memory and daily function in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Category: News Release
-
Georgetown Study Opens for Those With Inherited Genetic Risk for Alzheimer’s Disease
WASHINGTON — The Memory Disorders Program at Georgetown University Medical Center is seeking volunteers to participate in a study testing two agents to slow the onset and progression of Alzheimer’s disease. Cognitively normal individuals with a particular genetic risk of developing the disorder are being sought.
Category: News Release